Just Out at DAY 2⃣ #GUARDSymposium2024 🇪🇸 Sabine D. Brookman-May on interim data from ongoing studies with #TAR-200 (gemcitabine releasing system) #Sunrise1and #TAR210 (#erdafitinib releasing system) in patients with #NMIBC. Plus: Information about the intravesical placement of the

It was a pleasure to speak today at #GuardSymposium2024 about our current research J&J Innovative Medicine with #TAR210 #Erdafitinib and #TAR200 in patients with IR and HR #NMIBC #BladderCancer 👉Very nice summary👇 Thank you Dra. María Natalia Gandur Quiroga oncoalert

Intravesical erdafitinib demonstrates high response rates in #NMIBC with reduced toxicity. Roger Li and Sam S. Chang MD, MBA discuss the #TAR210, share insights, and highlight the efficacy of Erdafitinib, particularly in patients with FGFR alterations > bit.ly/3w78L4p

🔍 Roger Li provides commentary on the rationale, design, and potential impact of the #MoonRISe1 study, which focuses on #TAR210—a drug-eluting stent that delivers #erdafitinib directly to the #bladder—for intermediate-risk #NMIBC. 🧠 Learn More: buff.ly/3wEhw6x

Intravesical erdafitinib demonstrates high response rates in #NMIBC with reduced toxicity. Roger Li and Sam S. Chang MD, MBA discuss the #TAR210, share insights, and highlight the efficacy of Erdafitinib, particularly in patients with FGFR alterations > bit.ly/3w78L4p

Johnson & Johnson Highlights Data from the P-I Study of TAR-210 for Non-Muscle-Invasive Bladder Cancer (NMIBC) at AUA 2024 #johnsonandjohnson #tar210 #nonmuscleinvasivebladdercancer #clinicaltrial #phase1 #safety #efficacy #treatment #nmibc pharmashots.com/17363/johnson-…

#MoonRISe-1: Phase 3 study of #TAR210, an erdafitinib intravesical delivery system, vs intravesical chemotherapy in patients with IR #NMIBC with susceptible FGFR alterations. Presentation by Roger Li Moffitt Cancer Center. #AUA24 coverage by Zach Klaassen > bit.ly/3QxXr8F

Antoni Vilaseca presenting updated data on #TAR210 FIH study in patients with #FGFR+ #NMIBC today at #AUA24 ✅90% estimated 12 months RFS in BCG experienced HR NMIBC ✅90% CR in IR NMIBC #BladderCancer Johnson & Johnson Innovation #MyCompany #Erdafitinib

Intravesical erdafitinib demonstrates high response rates in #NMIBC with reduced toxicity. Roger Li and Sam S. Chang MD, MBA discuss the #TAR210, share insights, and highlight the efficacy of Erdafitinib, particularly in patients with FGFR alterations > bit.ly/3w78L4p

Hats off to jim catto for a terrific presentation evaluating oral #erdafitinib for #NMIBC. 6 mg dose appears reasonable in this setting. As he points out, eagerly awaiting #TAR210 approach which will be shared in a separate talk at #ESMO23!

#ESMO23 jim catto THOR-2 cohort 1 results of #erdafitinib vs intravesical chemo in HR #NMIBC + #FGFR alterations after prior BCG: ➡️RFS reduced by 72% ➡️Due to systemic erda side effects, #TAR210 being developed for local delivery 👉 more to be presented at #ESMO23 JNJInnovative Medicine

#ESMO23 Late breaker: FIH Study #TAR210 intravesical #Erdafitinib delivery system for #FGFR+ #UrothelialCarcinoma: 👉High recurrence free/complete response rate 👉11/13 evaluable patients (BCG exp. HR #NMIBC) + 13/15 (IR #NMIBC) recurrence free #AntoniVilaseca JNJInnovative Medicine

Looking forward to seeing new data on #BladderCancer and #Erdafitinib #TAR200 #TAR210 🥨 presented at #ESMO23 👉 Research targeting late and early stage disease #mUC, #NMIBC, #FGFR tumor agnostic JNJInnovative Medicine-J&JInnovativeMedicine

Novel intravesical therapies on the roll #ESMO23 #TAR210 and #TAR200 in HR NMIBC. Results will impress the audience I guess. Also proud to see Patrizia Giannatempo be a thought leader! #Sunrise-1 ESMO - Eur. Oncology Ashish M. Kamat, MD, MBBS Joshua Meeks Sia Daneshmand, M.D. Patrizia Giannatempo UroToday.com Ospedale San Raffaele